News

27 Companies Share 6.1 Million Dollars in 2019 Advanced Industries Accelerator Grants

Wednesday, May 22, 2019

Colorado BioScience Association congratulates the 27 companies recently recognized as valuable investments for the entire state by the Office of Economic Development and International Trade’s (OEDIT) Advanced Industries (AI) Grants Program. The growth and success of Colorado’s life science ecosystem would not be as robust as it is today without this valuable assistance from the state’s Advanced Industries (AI) Accelerator Grant Program. Special congratulations to the bioscience companies who were awarded funding this round:  

CMS Rolls Back Harmful Proposals in Medicare Part D

Monday, May 20, 2019

 

ArcherDX Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio

Wednesday, May 15, 2019

BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/-- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced the closing of an up to $60 million Series B financing round led by Perceptive Advisors. The investor syndicate also includes existing investors PBM Capital, Boulder Ventures, Longwood Fund and Peierls Foundation.  

Weekly Policy Update: CMS Proposed Rule is a Step Forward for the Coverage of Breakthrough Technologies

Monday, May 13, 2019

In late April, the Centers for Medicare and Medicaid Services (CMS) publicly released its FY 2020 Inpatient Prospective Payment System (IPPS) Proposed Rule. The rule is a critical step forward for coverage and payment of medical devices, and makes it more likely that breakthrough products will be covered and adequately paid for by CMS.  

Prima-Temp Announces New Leadership, Investment, and CE Mark Certification

Wednesday, May 08, 2019

BOULDER, Colo., May 3, 2019 /PRNewswire/ -- Boulder, Colorado based Prima-Temp, Inc. a developer and manufacturer of AI-assisted fertility management products, announced today that in March, it raised $5M in new funding from the Hungarian pharmaceutical company Gedeon Richter, and in April achieved CE mark certification for its Priya Fertility Sensor product. 

Weekly Policy Update: The Final Tally - 2019 Legislative Session Comes to a Close

Friday, May 03, 2019

CBSA has worked hard this session to advocate on behalf of the industry. We’ve worked with our members and partners to advance proposals that promote patient safety, protect patient access, and enhance workforce development efforts, while coordinating to convey concerns with problematic legislation and mitigate threats to the industry in Colorado. 

Weekly Policy Update: One Week Left - What Will Make It Across the Finish Line

Friday, April 26, 2019

  

CBSA Opposes Drug Importation and Continues to Advocate for Safe Policy to Reduce Patient Costs

Monday, April 22, 2019

Last week CBSA testified in the House Health and Insurance Committee in opposition to Senate Bill 005 - Import Prescription Drugs From Canada, which would require the Department of Health Care Policy and Financing to design a program to import prescription drugs from Canada for sale to Colorado consumers. CBSA expressed our concerns that opening up the U.S. supply chain would jeopardize safety by exposing patients to counterfeit, adulterated or unapproved drugs and would result in minimal savings for consumers. In fact, both the Department of Health and Human Services and the Congressional Budget Office have stated that savings from importation would be minimal; estimates suggest less than one percent.  

Weekly Policy Update: CBSA Applauds Introduction of House Bill to Permanently Repeal Medical Device Excise Tax

Friday, April 12, 2019

This week bipartisan legislation was introduced in the U.S. House of Representatives to permanently repeal the medical device excise tax. CBSA applauds the introduction of H.R. 2207, Protect Medical Innovation Act of 2019, which gets us one step closer to providing innovators the long-term certainty they need to support future job growth and sustainable, cutting-edge research and development.  

AdvaMed President and CEO Releases Statement On the House Bill To Repeal the Medical Device Tax

Thursday, April 11, 2019

WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on introduction of bipartisan legislation (H.R. 2207) in the U.S. House of Representatives to permanently repeal the medical device excise tax:

“America’s medical technology industry is facing a $20 billion tax increase at year-end, when the current medical device tax suspension expires. Urgent action is essential to protect future medtech innovations that benefit patients and to avoid putting good-paying U.S. jobs at risk.

“House introduction today of the ‘Protect Medical Innovation Act of 2019’ in the 116th Congress brings us one step closer to ensuring this innovation-stifling burden on the medtech industry never returns, supporting continued American leadership of this vital industry.

“We thank the bill’s lead sponsors, Reps. Ron Kind (D-Wis.), Jackie Walorski (R-Ind.), Scott Peters (D-Calif.), and Richard Hudson (R-N.C.) for their leadership on this issue. This bill – and the strong bipartisan support they have gathered – reflect the high priority this Congress places on patients, jobs, and future investment.

“While past suspensions of the medical device tax have enabled manufacturers to invest in R&D, infrastructure and new hiring – which in turn benefits patients and the U.S. economy – these benefits are at risk. Now that bipartisan legislation to permanently repeal the device tax has been introduced in both the House and Senate, AdvaMed will urge Congress and the administration to act as expeditiously as possible to get rid of the tax once and for all this year.”

 
Continue Reading